Novo Nordisk, a diabetes-focused multinational pharma, has launched INNOVO, a platform designed to promote China innovation by connecting Novo Nordisk with China academic institutions, bio-tech startups and incubators. The company aims to accelerate its scientific research though the relationships. Novo Nordisk has a long history in China. It set up a China office in 1994 and established an R&D center in Beijing in 1997, the first multinational biopharma to do so. The Novo Nordisk Research Center in China will be in charge of running INNOVO. More details.... Stock Symbol: (NYSE: NVO)